Project Grant R01CA296645
- Federal Project Grant Summary Duke University's Office of Research Administration has received a $610,459 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026, through April 30, 2031. The award funds fundamental research into olfactory neuroblastoma (ONB), a rare and life-threatening tumor, with the objective of identifying key genetic drivers and mechanisms underlying cell fate plasticity in this disease. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration within the School of Medicine a Project Grant totaling $109,076.00 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025. The award supports biomedical research training and career development initiatives focused on cancer research through September 1, 2029. This project grant funds the institution's capacity to provide integrated...
- Federal Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine Division received a $110,228 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded December 1, 2026, with completion scheduled for May 31, 2029. This award funds biomedical research training and workforce development focused on pancreatic ductal adenocarcinoma (PDAC) microenvironment remodeling. The project investigates how...
- Federal Grant Award Summary The National Cancer Institute awarded New York University School of Medicine a $595,993 Project Grant (CFDA 93.395: Cancer Treatment Research) effective July 16, 2026, through July 31, 2031, to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a robust platform technology enabling direct and selective manipulation of intracellular driver oncoproteins and their interactions. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $410,933 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on March 18, 2026, with completion anticipated by February 29, 2028. This exploratory research initiative (R21) focuses on developing next-generation small interfering RNA (siRNA) therapeutics to treat metastatic castration-resistant prostate cancer (mCRPC). The primary deliverable is the...
- Federal Project Grant Award Summary Funding Agency and Program: The National Cancer Institute awards $487,056 under the Cancer Biology Research program (CFDA 93.396) to the University of Florida Division of Sponsored Research for a five-year project period beginning July 1, 2026 and concluding June 30, 2031. Research Deliverables: The award funds research to elucidate mechanisms by which LKB1 (Serine/Threonine Kinase 11) tumor suppressor gene inactivation drives immune evasion and therapeutic...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $661,721 Project Grant to the University of California, San Diego for "Systematic Functional Mapping and Interrogation of Oncogenic Intrinsically Disordered Regions" under the Cancer Biology Research program (CFDA 93.396). The award, effective April 1, 2026 through March 31, 2031, supports fundamental cancer biology research aimed at identifying cancer cell vulnerabilities and drug resistance...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $588,677 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona, with an award date of July 1, 2026, and a project completion date of June 30, 2031. The research focuses on identifying the mechanisms by which oxygen-dependent centrosome instability drives prostate cancer progression. Specifically, the project investigates how hypoxia induces centrosome loss and...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
The National Cancer Institute (NCI) awarded $606,219 to the University of Miami's Office of Research Administration–School of Medicine on July 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project through June 30, 2031. The project investigates signal transduction, cell biology, and molecular pharmacology of OR51E1, an olfactory G protein-coupled receptor (GPCR) ectopically expressed in prostate cancer and other non-olfactory tissues. The research deliverables include characterization of OR51E1's signaling mechanisms and therapeutic potential through the application of novel small-molecule agonists and antagonists identified via the investigator's high-throughput screening platform—over 100 agonists and approximately five antagonists that demonstrate 100–1,000-fold greater potency and selectivity compared to the endogenous ligand butyrate. The project builds on the investigator's prior technical advances in large-scale functional expression of olfactory receptors and development of a high-throughput screening platform for GPCRs. Expected outputs include mechanistic insights into OR51E1 signaling cascades, validation of the identified compounds' biological activity, and preliminary data supporting exploration of OR51E1 as a therapeutic target in prostate cancer and other pathological conditions. This research aligns with NCI's Cancer Biology Research program objectives to advance fundamental understanding of cancer cell biology and mechanisms underlying neoplastic disease.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $606.2k | 7/6/26 |